<DOC>
	<DOCNO>NCT02382159</DOCNO>
	<brief_summary>1 . Target disease : Patients combine dyslipidemia accompany type 2 diabetes do exogenous visit hospitalization Jan 2010 June 2014 . 2 . Study objective : 1 . The objective study Identifying lipid parameter variation treat patient dyslipidemia type 2 diabetes 3±1 month . 2 . After treat patient dyslipidemia type 2 diabetes 3±1 month , identify reason change method drug dosage pharmacotherapy . 3 . If drug dosage pharmacotherapy change , Identifying lipid parameter variation treat patient alter drug 3±1 month ,</brief_summary>
	<brief_title>A Observational Study Evaluate Lipid-lowering Drug Its Effect Parameters Dyslipidemia Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hypolipidemic Agents</mesh_term>
	<criteria>Among patient , hospitalize visited Outpatient Department OPD , dyslipidemia type 2 diabetes . 1 . Patients result lipid parameter test baseline lipidlowering drug least 3 month . 2 . Patients result lipid paraneter test ( LDLC ≥100mg/dL , TG ≥150mg/dL ) baseline . 3 . Patients receive lipid lower drug fr least 2 month prior baseline . 4 . Patients ' age ＞ 20 year ＜75 year . 1 . Patients ahs HbA1c≥9 % 2 . Patients result lipid parameter test baseline baseline lipidlowering drug least 3 month 3 . Patients history drug discontinuation incresed liver enzyme rhabdomyolysis . 4 . Patients receive lipidlowering drug TZD ( Thiazolidinediones ) study period 5 . Renal abnormality 6 . Alcoholism Alcohol abuse 7 . Patients treated Steroids . 8 . Pregnant lactate woman 9 . Patients judge suitable study Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>